IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v38y2020i5d10.1007_s40273-019-00881-7.html
   My bibliography  Save this article

Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements

Author

Listed:
  • Pierre Johansen

    (Novo Nordisk A/S)

  • Daniel Howard

    (DRG Abacus)

  • Ryan Bishop

    (DRG Abacus)

  • Søren Ilsøe Moreno

    (Novo Nordisk A/S)

  • Kristine Buchholtz

    (Novo Nordisk A/S)

Abstract

Background Non-alcoholic steatohepatitis (NASH) is a severe, typically progressive form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NASH is increasing, driven partly by the global increase in obesity and type 2 diabetes mellitus (T2DM), such that NASH is now a leading cause of cirrhosis. There is currently an unmet clinical need for efficacious and cost-effective treatments for NASH; no pharmacologic agents have an approved indication for NASH. Objective Our objective was to summarise and critically appraise published health economic models of NASH, to evaluate their quality and suitability for use in the assessment of novel treatments for NASH, and to identify knowledge gaps, challenges and opportunities for future modelling. Methods A systematic literature review was performed using the MEDLINE, Embase, Cochrane Library and EconLit databases to identify published health economic analyses in patients with NAFLD or NASH. Supplementary hand searches of grey literature were also performed. Articles published up to November 2019 were included in the review. Quality assessment of identified studies was also performed. Results A total of 19 articles comprising 16 unique models including either NAFLD as a whole or NASH alone were included in the review. Structurally, most models had a state-transition component; in terms of health states, two different approaches to early disease states were used, modelling either progression through fibrosis stages or NAFLD/NASH-specific health states. Conditions that frequently co-exist with NASH, such as obesity, T2DM and cardiovascular disease were not captured in models identified here. Late-stage complications such as cirrhosis, decompensated cirrhosis and hepatocellular carcinoma were consistently included, but input data (e.g. costs, utilities and transition probabilities) for late-stage complications were frequently sourced from other liver disease areas. The quality of included studies was heterogenous, and only a small proportion of studies reported internal and external validation processes. Conclusion The health economic models identified in this review are associated with limitations primarily driven by a lack of NASH-specific data. Identified models also largely overlooked the intricate association between NASH and other conditions, including obesity and T2DM, and did not capture the increased risk of cardiovascular events associated with NASH. High-quality, transparent, validated health economic models of NASH will be required to evaluate the cost effectiveness of treatments currently in development, particularly compounds that may target other non-hepatic outcomes.

Suggested Citation

  • Pierre Johansen & Daniel Howard & Ryan Bishop & Søren Ilsøe Moreno & Kristine Buchholtz, 2020. "Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements," PharmacoEconomics, Springer, vol. 38(5), pages 485-497, May.
  • Handle: RePEc:spr:pharme:v:38:y:2020:i:5:d:10.1007_s40273-019-00881-7
    DOI: 10.1007/s40273-019-00881-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-019-00881-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-019-00881-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Seamus Kent & Frauke Becker & Talitha Feenstra & An Tran-Duy & Iryna Schlackow & Michelle Tew & Ping Zhang & Wen Ye & Shi Lizheng & William Herman & Phil McEwan & Wendelin Schramm & Alastair Gray & Jo, 2019. "The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood," PharmacoEconomics, Springer, vol. 37(11), pages 1305-1312, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Elliot B. Tapper & Jagpreet Chhatwal, 2020. "We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can," PharmacoEconomics, Springer, vol. 38(5), pages 427-429, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Paul Tappenden & J. Jaime Caro, 2019. "Improving Transparency in Decision Models: Current Issues and Potential Solutions," PharmacoEconomics, Springer, vol. 37(11), pages 1303-1304, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:38:y:2020:i:5:d:10.1007_s40273-019-00881-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.